CureVac (CVAC) Shares Drop as BioNTech Finalizes Acquisition and Delisting Plans CureVac N.V. (CVAC) shares experienced a significant decline today, falling -14.3154% to close near $4.13.
This sharp movement follows BioNTech's official announcement that it has successfully completed its acquisition of the company after a months-long process.
The drop marks a pivotal moment for the biotechnology firm as it transitions from a publicly traded entity to a subsidiary of BioNTech. With the exchange offer now expired, the company is moving toward a total reorganization that will see CureVac shares cease trading on public markets early next year.
Key Takeaways
- CureVac shares fell -14.3154% today, reaching their lowest levels since June 2025.
- BioNTech secured 86.75% of outstanding shares, surpassing the 80% minimum threshold required for the deal.
- The acquisition values CureVac at approximately $1.25 billion, with an offer price of $5.46 per share.
- CVAC is expected to be delisted in January 2026 following a compulsory acquisition of remaining shares.
BioNTech Consolidation: The End of Independent Trading for CureVac
BioNTech SE confirmed the successful closing of its acquisition on December 18, 2025, following the expiration of the exchange offer's subsequent offering period. A total of 195,341,219 shares were validly tendered, representing approximately 86.75% of CureVac’s outstanding stock.
This level of participation allowed BioNTech to move forward with the final stages of the merger, which began with a definitive purchase agreement in June 2025.
The acquisition marks the end of CureVac's history as an independent public company. BioNTech has already begun implementing management changes, with former CureVac board members resigning to make way for BioNTech executives.
Trading volume today reached 971,305, which sat below the 20-day average of 1,354,207, as the market reacted to the culmination of the buyout.
The company confirmed that a post-offer reorganization will take place, leading to a compulsory acquisition of any remaining shares in January 2026. This process will ensure that BioNTech gains 100% ownership of the firm.
Consequently, CureVac shares will no longer be available for independent trading once the January reorganization is complete.
Strategic Rationale: Boosting BioNTech’s mRNA and Oncology Portfolio
This transaction represents a major strategic consolidation within the mRNA technology sector. By absorbing CureVac, BioNTech aims to strengthen its capabilities in mRNA design, delivery formulations, and manufacturing.
The move is specifically designed to support BioNTech’s long-term oncology strategy, providing deeper resources for the development of cancer therapies.
Prof. Ugur Sahin, CEO of BioNTech, stated that the acquisition “deepens their mRNA technology platform, expanding potential therapeutic applications.” This integration is expected to allow BioNTech to leverage CureVac’s intellectual property and technical expertise to accelerate its own clinical pipeline.
The consolidation comes at a time of high competition in the mRNA space. While other companies like Moderna and Arcturus saw modest gains today, CureVac’s decline was viewed by analysts as acquisition-specific.
The merger allows BioNTech to solidify its unique position in the field, combining the research strengths of two of the most prominent European mRNA pioneers.
What Happens to Current CVAC Shareholders?
For investors still holding CureVac stock, the next steps involve a mandatory conversion process. Because BioNTech secured more than the 80% minimum acceptance threshold, it has the authority under Dutch law to initiate a compulsory acquisition.
According to reports from WELT, the remaining shares will be converted into BioNTech American Depositary Shares (ADS) during January 2026.
The initial valuation of the deal was approximately $1.25 billion (1.08 billion Euro), based on an offer price of $5.46 per share. Today’s trading saw the stock price fluctuate within a day range of $4.13 to $4.66.
This price point is significantly lower than the 52-week high of $5.72 and represents the lowest close for the stock since June 11, 2025, when it hit $4.07.
The transition to BioNTech ADS was approved during an extraordinary general meeting. Shareholders who did not participate in the initial tender will receive the same consideration as those who did, though the timing is now tied to the January 2026 reorganization.
This transition effectively ends the “Hold” consensus that many analysts had maintained leading up to the deal's expiration.
Market Reaction and Industry Performance
CureVac’s -14.3154% drop today caused it to significantly underperform the broader biotechnology industry, which saw an average decrease of only -2.98%. The stock has faced a difficult period leading up to this closing, with a 1-month change of -21.7803% and a 6-month change of -24.7723%.
When compared to its industry peers, the disparity in performance is clear. Legend Biotech Corporation (LEGN) fell 1.0624%, and Structure Therapeutics Inc. (GPCR) declined 2.8196%.
Even companies experiencing higher volatility, such as Verastem, Inc. (VSTM) which dropped 7.8704%, did not see the double-digit percentage decline that hit CureVac.
MarketBeat reported just yesterday that CureVac had maintained an average “Hold” recommendation from analysts. This consensus indicated that most market experts saw little room for growth outside of the acquisition terms.
The current price movement suggests the market is now fully pricing in the final delisting and the end of CureVac’s independent valuation. For investors looking to identify opportunities or risks, utilizing best free stock screeners can be a valuable approach.
The Bottom Line
The sharp decline in CureVac’s stock price today reflects the final stages of its acquisition by BioNTech. With the majority of shares now tendered and a clear path toward delisting in January 2026, the company’s era as an independent entity is effectively over.
For the biotechnology sector, the deal represents a significant consolidation of mRNA technology under the BioNTech umbrella, while for CVAC shareholders, it marks the beginning of the mandatory conversion into BioNTech ADS.
Read More
- Best Stock Analysis Apps & Softwares
- Best Free Stock Research Tools & Websites
- Fundamental Analysis Checklist: What to Look for in a Stock
- What Happens to Stock When a Company Goes Bankrupt?
- Why Do Companies Buy Back Stock?
